Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company headquartered in Jerusalem, Israel, with a dual focus on developing innovative inflammation and immunology (I&I) biological products and providing Contract Development and Manufacturing Organization (CDMO) services. The company's mission is to elevate drug development. Formerly known as BiondVax Pharmaceuticals Ltd., the company rebranded in September 2023 to reflect its new strategic direction.

The company operates two complementary business units. Its in-house research and development efforts are centered on nanosized VHH antibodies (NanoAbs) for conditions such as psoriasis, asthma, and infectious diseases like COVID-19. Additionally, Scinai is advancing PC111, a fully human anti-sFasL monoclonal antibody, for the treatment of severe dermatological conditions including pemphigus vulgaris and Stevens-Johnson syndrome/toxic epidermal necrolysis. The second business unit, Scinai Bioservices, offers boutique CDMO services, encompassing biological drug development, analytical methods development, clinical cGMP manufacturing, and support for pre-clinical and clinical trials for early-stage biotech companies.

Amir Reichman has served as the CEO since March 2021. In April 2026, Scinai completed a strategic reorganization, establishing Scinai Biopharma Services Ltd. as a dedicated CDMO subsidiary, following its February 2026 acquisition of Recipharm Israel (Yavne site). This move aims to streamline operations by separating the CDMO unit from the R&D-focused therapeutics division. The company also recently secured $2.61 million in private placement financing in April 2026 to further expand its CDMO capabilities and advance its immunotherapy pipeline. Scinai has also expanded its CDMO presence by establishing a U.S.-based subsidiary, Scinai Bioservices Inc., to cater to the American market.